News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Yaupon Therapeutics Inc. Submits New Drug Application for Proprietary Gel Formulation of Mechlorethamine Hydrochloride


7/28/2011 7:09:27 AM

MALVERN, Pa.--(BUSINESS WIRE)--Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine). Yaupon is seeking U.S. marketing approval of its mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). Yaupon’s formulation is a water-soluble, greaseless topical gel.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES